Table 1.
Activity | Agonista | Evidencea | Figure |
---|---|---|---|
HEK293 kidney cells | |||
Gs-mediated cAMP production | NECA, Bay | GsKO | 2A–C |
Gs-mediated ERK1/2 stimulation | NECA | GsKO, CTX | 3A,B |
Gs-mediated ERK1/2 via PKA, EPAC | NECA | H89, ESI | 3E |
ERK1/2 activity via PKC | NECA | GO | 3A |
Gi-mediated ERK1/2 stimulation | NECA | PTX | 3A,D,F |
Gq-mediated Ca2+ mobilization | NECA | UBO, Gq/11KO | 4A,C |
A2B-overexpressing HEK293 kidney cells | |||
Gs-mediated cAMP production left-shifted | NECA | C/R curve | 5C |
T24 bladder cancer cells | |||
Gs-mediated cAMP production | NECA, Bay | PTX/UBO (−) | 6 |
ERK1/2 activity via PKC | NECA | GO | 7A |
Gi-mediated ERK1/2 stimulation | NECA | PTX | 7C |
Gs/PKA-suppressed ERK1/2 activity | NECA, Bay | CTX, H89 | 7A,C–E |
ERK1/2 activity suppressed by EPAC2 | NECA | HJC0350 | 7D |
ERK1/2 stimulation requires PKC | NECA | GO | 7D |
Gi-mediated Ca2+ mobilization | NECA | PTX | 8 |
1321N1 astrocytoma cells | |||
Gs-mediated cAMP production | NECA | UBO/PTX (−) | 9 |
Gs-suppressed ERK1/2 activity | NECA | forsk, CTX | 10A,B |
Gs-suppression of ERK1/2 is PKC-depend. | NECA | GO | 10C |
ERK1/2 inhibition via EPAC1 | NECA | CE3F4 | 10C |
Gi-stimulated ERK1/2 activity | NECA | PTX | 10B |
ERK1/2 inhibition (other agonists) | Bay, MRS5911, MRS3997 | 10D | |
Lack of A2BAR-induced Ca2+ mobilization | NECA | Ca2+ dye | 11 |
Bay, BAY60-6583; C/R, concentration-response; ESI, ESI-09; forsk, forskolin; GO, GO6983; UBO, UBO-QIC.